Bone and type 2 diabetes: effects of power and aerobic exercise

Not Applicable

• Conditions: Healthy females; Type 2 diabetes; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12608000131358
• Lead Sponsor: Victoria University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-03-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

Inclusion criteria for the non-diabetic group: the non-diabetic group will be matched for age, body mass index (BMI) and menopausal status to the diabetic group and will have fasting blood glucose < 5.6 mmol/L.

Inclusion criteria for individuals with T2DM: Volunteers with fasting plasma glucose =7.0 mmol/L (Report of the expert committee on the diagnosis and classification of diabetes mellitus, 2003) and with HbA1C<8% will be included. In addition, volunteers treated with diet alone and/or use stable doses of metformin for at least 3 months will be included.

Exclusion Criteria

Exclusion criteria for the non-diabetic group. Fasting blood glucose <5.6 mmol/L, or individuals who are unable to exercise. In addition, participants who are already involved in regular vigorous physical training in the preceding 6 months.

Exclusion criteria individuals with T2DM. Individuals with unstable T2DM, individuals on sulfonylureas or insulin therapy and individuals who have participated in regular vigorous resistance training in the preceding 6 months will be excluded from the study. Also, patients unable to exercise will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ncarboxylated osteocalcin (unc-OC) will be <br>analysed based on a sandwich type electro-chemiluminescence immunoassay (ECLIA) utilizing anti-OCG3 mouse monoclonal antibody labelled with Ruthenium (Ru) which luminates with electric stimuli. Magnetic beads bound to anti GluOC 4-5 mouse monoclonal antibody is used as a solid phase. After binding the unc-OC in the sample with the GluOC4-5 bound beads and Ru labelled OCG3, an electric impulse is applied via an electrode. The level of luminescence for the Ru complexes bound to solid phase antibody reflects the amount of unc-OC in the sample. The concentration of the unc-OC in the sample is measured by comparing the sample's luminescence to that of a calibrated solution of known unc-OC standards[Baseline, 3, 6 and 18 months]

Secondary Outcome Measures

Name	Time	Method
Clinical outcomes (lipids and fasting glucose will be analysed using SYNCHRON LX System/Lxi725, Beckman Coulter Inc, CA, USA) )<br>Anthropometric measurements (fat, muscle and bone density (using Dual-energy X-ray absorptiometry, DXA)<br>Functional capacity (physical performance test)<br>Quality of life (SF-36 and the cardiac depression scale, CDS).[Baseline, 3, 6 and 18 months]